Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

Bayer CropScience share price today

BAYERCROPAgrochemicalStandalonePrices to 18 Nov 2026Results to Sep 2026

Price, 200-day average and NIFTY 500

The price is 18.8% below its 200-day average and 85 points behind the NIFTY 500 over 5 years

18 Nov 2026₹3,351.80Over 5 years: Bayer CropScience −29.3%, NIFTY 500 +55.7%
₹4,000₹6,000Nov 22Nov 24Nov 26

Price growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y−26.2%3Y−14.5%/yr5Y−6.7%/yr10Y−1.5%/yr

EPS and P/E

EPS ₹165.90, up 22% in a year; P/E 20.2

18 Nov 2026₹165.90 EPS
Mar 22
Jun 22
Sep 22
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
Nov 26
₹0₹200

EPS growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+22.5%3Y−4.1%/yr5YToo short10YToo short

Revenue and margins

Revenue down on a year for 2 quarters in a row; operating margin 17.4%

Sep 2026 quarter₹1,251 crore−19.4% on ₹1,553 crore a year earlier · NPM 13.3%
Dec 21
Mar 22
Jun 22
Sep 22
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
0₹2,000

Revenue: 1Y change, then growth a year; margins are averages

Revenue growth1Y−5.0%3Y+3.4%/yr to Mar5Y+5.9%/yr to Mar10Y+7.4%/yr to Mar
OPM average3Y14.8%5Y16.3% to Mar
NPM average3Y12.1%5Y13.0% to Mar

Return on capital

ROCE was 29.1% for the year to Mar 2026, down from 31.3% in the year to Mar 2021

Year to Mar 202629.1% ROCE
20%30%Mar 22Mar 24Mar 26

ROCE average

1Y3Y5Y10Y1Y29.1% to Mar3Y29.2% to Mar5Y30.5% to Mar10Y28.3% to Mar

Profit and cash

Cash from operations was 92% of profit over five years, 156% in the year to Mar 2026

Yearly profit, cash from operations and free cash flow, ₹ crore

FY26₹1,078 crore operating cashProfit ₹689 crore · Free cash ₹1,039 crore
FY22
FY23
FY24
FY25
FY26
0₹1,250

Profit growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+22.5%3Y−3.1%/yr to Mar5Y+6.9%/yr to Mar10Y+8.1%/yr to Mar

Reinvestment

Capex was ₹40 crore in the year to Mar 2026, 0.4 times depreciation

FY26₹40 crore capexWork in progress ₹127 crore
FY22
FY23
FY24
FY25
FY26
0₹150

Capex growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+54.7% to Mar3Y−19.8%/yr to Mar5YToo short10YToo short

Borrowings

Debt ÷ equity 0.02 at 30 Sep 2026; profit covered interest 47.6x over the last four quarters

Sep 2026 balance sheet0.02 debt ÷ equityNet cash ₹472 crore
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
0125x

Safety

Now3Y ago
Debt ÷ equity0.023Y ago0.02
Int. cover47.6x3Y ago46.1x

Operating health

Working capital fell from 61 to 56 days in 5 years

Year to Mar 202656 days working capital
100300Mar 22Mar 24Mar 26
Working cap.561Y−323Y−305Y−5
Debtor721Y+93Y+35Y+7
Inventory2891Y−303Y+215Y+63

OwnershipInsufficient history, from Mar 2023Insufficient history, from Mar 2023

FIIs own 3.95%, up 0.15 points in a year. Promoters hold 71.44%

Share of the company held, %, by quarter end

Sep 2026 quarter3.95% FIIs
0%60%Sep 23Sep 24Sep 25Sep 26

Change in holding, in points

FIIs1Y+0.153Y+0.65
Promoters1Y0.003Y0.00

Bayer CropScience Ltd · BAYERCROP · Pesticides/Agrochemicals · price as of the 18 November 2026 close, updated every trading day · results updated weekly

Bayer CropScience share price today: ₹3,351.80 at the close on 18 November 2026, down 26.2% in a year. Bayer CropScience (BAYERCROP) is worth ₹15,064 crore, trades at a P/E of 20.2 and has closed between ₹3,256.70 and ₹4,898.20 over the past 52 weeks. Latest change: profit up on a year earlier for 7 quarters in a row.

Getting betterBusiness trend from the last 12 quarters
₹3,351.80Price −26.2% in a year
20.2×P/E lower than 100% of the last 10 years
₹1,251 CrRevenue (Sep 2026) −19.4% on a year ago
₹166 CrProfit (Sep 2026) +8.5% on a year ago
17.4%Operating margin +4.2 points on a year ago
29.1%ROCE year to Mar 2026
29.4%ROIC against a 12.0% cost of capital: +17.4 points

Bayer CropScience Ltd's earnings have grown faster than its share price. Earnings per share grew +22.5% in a year while the price moved −26.2%.

The main question: earnings per share (last four quarters) moved +22.5% while the share price moved −26.2%.

The price has been falling for 59 weeks, and the P/E is lower than 100% of its own last 10 years. Over the last four quarters, results have been improving, with profit +8.5% on a year earlier, and 115% of the last 3 years' profit came in as cash. What will decide it: whether the price catches up with earnings that have already grown.

What is the Bayer CropScience share price today?

Bayer CropScience Ltd's share price was ₹3,351.80 at the close on 18 November 2026. It has been falling for 59 weeks. That is 18.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹3,257 and ₹4,898, and at that close it sat 6% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Bayer CropScience Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 32 weeks running.

Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?

Ahead in 204 of 550 weeks

Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?
Week13-week return vs NIFTY 500
11 Mar 2016no NIFTY 500 reading
18 Mar 2016no NIFTY 500 reading
23 Mar 2016no NIFTY 500 reading
1 Apr 2016no NIFTY 500 reading
8 Apr 2016no NIFTY 500 reading
13 Apr 2016no NIFTY 500 reading
22 Apr 2016no NIFTY 500 reading
29 Apr 2016no NIFTY 500 reading
6 May 2016no NIFTY 500 reading
13 May 2016no NIFTY 500 reading
20 May 2016no NIFTY 500 reading
27 May 2016no NIFTY 500 reading
3 Jun 2016no NIFTY 500 reading
10 Jun 2016+2.7%
17 Jun 2016−0.4%
24 Jun 2016−2.6%
1 Jul 2016−5.5%
8 Jul 2016−2.0%
15 Jul 2016−8.6%
22 Jul 2016−5.5%
29 Jul 2016−11.0%
5 Aug 2016−8.8%
12 Aug 2016−11.0%
19 Aug 2016−10.4%
26 Aug 2016−4.6%
2 Sep 2016−5.4%
9 Sep 2016−8.3%
16 Sep 2016−5.5%
23 Sep 2016−2.1%
30 Sep 2016+8.9%
7 Oct 2016+3.1%
14 Oct 2016+11.9%
21 Oct 2016+8.2%
30 Oct 2016+5.0%
4 Nov 2016+1.7%
11 Nov 2016+2.7%
18 Nov 2016+3.7%
25 Nov 2016+1.4%
2 Dec 2016+6.8%
9 Dec 2016+7.1%
16 Dec 2016+8.7%
23 Dec 2016+4.8%
30 Dec 2016+0.3%
6 Jan 2017−1.5%
13 Jan 2017−5.6%
20 Jan 2017+0.1%
27 Jan 2017−3.9%
3 Feb 2017+1.0%
10 Feb 2017−5.0%
17 Feb 2017−8.0%
23 Feb 2017−11.2%
3 Mar 2017−15.1%
10 Mar 2017−16.5%
17 Mar 2017−21.2%
24 Mar 2017−23.6%
31 Mar 2017−24.9%
7 Apr 2017−21.9%
13 Apr 2017−17.6%
21 Apr 2017−8.2%
28 Apr 2017+0.4%
5 May 2017+0.0%
12 May 2017+1.7%
19 May 2017+7.5%
26 May 2017+3.1%
2 Jun 2017+18.7%
9 Jun 2017+14.9%
16 Jun 2017+14.3%
23 Jun 2017+16.1%
30 Jun 2017+17.8%
7 Jul 2017+17.0%
14 Jul 2017+13.5%
21 Jul 2017+0.1%
28 Jul 2017−3.1%
4 Aug 2017−8.0%
11 Aug 2017−9.5%
18 Aug 2017−11.7%
24 Aug 2017−9.5%
1 Sep 2017−22.3%
8 Sep 2017−17.1%
15 Sep 2017−14.7%
22 Sep 2017−18.2%
29 Sep 2017−19.0%
6 Oct 2017−20.5%
13 Oct 2017−22.7%
19 Oct 2017−21.3%
27 Oct 2017−22.2%
3 Nov 2017−21.9%
10 Nov 2017−16.0%
17 Nov 2017−13.0%
24 Nov 2017−8.3%
1 Dec 2017−5.7%
8 Dec 2017−6.5%
15 Dec 2017−8.1%
22 Dec 2017+0.6%
29 Dec 2017+4.6%
5 Jan 2018+11.2%
12 Jan 2018+18.4%
19 Jan 2018+12.5%
25 Jan 2018+13.5%
2 Feb 2018+6.7%
9 Feb 2018−2.0%
16 Feb 2018−4.1%
23 Feb 2018−4.2%
1 Mar 2018−6.7%
9 Mar 2018+3.0%
16 Mar 2018+4.3%
23 Mar 2018+3.1%
28 Mar 2018+0.4%
6 Apr 2018+1.9%
13 Apr 2018−3.7%
20 Apr 2018+4.1%
27 Apr 2018+3.6%
4 May 2018+8.0%
11 May 2018+10.3%
18 May 2018+18.1%
25 May 2018+19.0%
1 Jun 2018+23.4%
8 Jun 2018+12.9%
15 Jun 2018+9.6%
22 Jun 2018+5.8%
29 Jun 2018+5.4%
6 Jul 2018+1.0%
13 Jul 2018+2.5%
20 Jul 2018−4.5%
27 Jul 2018−4.9%
3 Aug 2018−4.6%
10 Aug 2018−6.2%
17 Aug 2018−16.8%
24 Aug 2018−17.1%
31 Aug 2018−14.2%
7 Sep 2018−12.6%
14 Sep 2018−9.6%
21 Sep 2018−10.5%
28 Sep 2018−4.3%
5 Oct 2018−1.6%
12 Oct 2018+3.1%
19 Oct 2018+5.1%
26 Oct 2018−4.1%
2 Nov 2018−3.6%
9 Nov 2018+2.3%
16 Nov 2018+7.4%
22 Nov 2018+8.0%
30 Nov 2018+6.5%
7 Dec 2018+7.4%
14 Dec 2018+4.2%
21 Dec 2018+3.9%
28 Dec 2018−1.8%
4 Jan 2019−4.3%
11 Jan 2019−6.8%
18 Jan 2019−4.5%
25 Jan 2019+7.4%
1 Feb 2019+10.7%
8 Feb 2019+6.5%
15 Feb 2019+7.7%
22 Feb 2019+7.2%
1 Mar 2019+0.6%
8 Mar 2019−2.1%
15 Mar 2019−4.0%
22 Mar 2019−2.3%
29 Mar 2019−3.1%
5 Apr 2019−6.3%
12 Apr 2019−5.7%
18 Apr 2019−8.2%
26 Apr 2019−12.4%
3 May 2019−11.4%
10 May 2019−7.7%
17 May 2019−10.5%
24 May 2019−14.4%
31 May 2019−19.2%
7 Jun 2019−22.3%
14 Jun 2019−20.4%
21 Jun 2019−23.7%
28 Jun 2019−21.0%
5 Jul 2019−19.1%
12 Jul 2019−18.1%
19 Jul 2019−18.3%
26 Jul 2019−17.8%
2 Aug 2019−20.6%
9 Aug 2019−18.2%
16 Aug 2019−20.7%
23 Aug 2019−14.9%
30 Aug 2019−9.8%
6 Sep 2019−5.7%
13 Sep 2019−4.1%
20 Sep 2019+5.4%
27 Sep 2019−0.6%
4 Oct 2019+2.0%
11 Oct 2019+1.6%
18 Oct 2019−1.2%
27 Oct 2019+1.1%
1 Nov 2019+16.0%
8 Nov 2019−0.7%
15 Nov 2019+1.3%
22 Nov 2019+9.9%
29 Nov 2019+9.3%
6 Dec 2019+7.3%
13 Dec 2019+3.0%
20 Dec 2019−2.5%
27 Dec 2019+2.5%
3 Jan 2020+3.7%
10 Jan 2020+6.9%
17 Jan 2020+19.7%
24 Jan 2020+19.1%
1 Feb 2020+9.4%
7 Feb 2020+27.3%
14 Feb 2020+26.4%
20 Feb 2020+12.3%
28 Feb 2020+23.8%
6 Mar 2020+24.0%
13 Mar 2020+37.6%
20 Mar 2020+25.8%
27 Mar 2020+18.0%
3 Apr 2020+18.6%
9 Apr 2020+24.8%
17 Apr 2020+18.1%
24 Apr 2020+22.9%
30 Apr 2020+22.6%
8 May 2020+27.3%
15 May 2020+28.6%
22 May 2020+30.0%
29 May 2020+38.0%
5 Jun 2020+35.7%
12 Jun 2020+27.2%
19 Jun 2020+54.0%
26 Jun 2020+63.1%
3 Jul 2020+58.8%
10 Jul 2020+32.1%
17 Jul 2020+25.6%
24 Jul 2020+22.1%
31 Jul 2020+16.4%
7 Aug 2020+11.0%
14 Aug 2020+11.2%
21 Aug 2020+5.2%
28 Aug 2020−11.3%
4 Sep 2020−4.1%
11 Sep 2020−6.0%
18 Sep 2020−7.7%
25 Sep 2020−6.5%
1 Oct 2020−12.5%
9 Oct 2020−11.8%
16 Oct 2020−7.4%
23 Oct 2020−14.3%
30 Oct 2020−7.9%
6 Nov 2020−18.2%
14 Nov 2020−26.9%
20 Nov 2020−27.1%
27 Nov 2020−27.3%
4 Dec 2020−29.4%
11 Dec 2020−29.3%
18 Dec 2020−35.7%
24 Dec 2020−32.0%
1 Jan 2021−29.2%
8 Jan 2021−21.0%
15 Jan 2021−22.9%
22 Jan 2021−16.5%
29 Jan 2021−19.3%
5 Feb 2021−23.9%
12 Feb 2021−20.9%
19 Feb 2021−13.7%
26 Feb 2021−11.8%
5 Mar 2021−14.3%
12 Mar 2021−14.0%
19 Mar 2021−12.1%
26 Mar 2021−16.4%
1 Apr 2021−10.1%
9 Apr 2021−14.9%
16 Apr 2021−12.4%
23 Apr 2021−10.9%
30 Apr 2021−9.9%
7 May 2021−5.5%
14 May 2021+4.8%
21 May 2021−0.1%
28 May 2021−5.1%
4 Jun 2021−3.7%
11 Jun 2021−2.3%
18 Jun 2021+1.0%
25 Jun 2021+0.8%
2 Jul 2021−1.4%
9 Jul 2021−0.8%
16 Jul 2021+4.0%
23 Jul 2021−0.6%
30 Jul 2021−2.4%
6 Aug 2021−2.0%
13 Aug 2021−0.3%
20 Aug 2021−4.4%
27 Aug 2021−7.9%
3 Sep 2021−6.8%
9 Sep 2021−10.4%
17 Sep 2021−16.3%
24 Sep 2021−16.6%
1 Oct 2021−18.2%
8 Oct 2021−20.4%
14 Oct 2021−26.6%
22 Oct 2021−25.6%
29 Oct 2021−24.1%
4 Nov 2021−28.0%
12 Nov 2021−33.6%
18 Nov 2021−25.0%
26 Nov 2021−15.8%
3 Dec 2021−15.3%
10 Dec 2021−14.5%
17 Dec 2021−7.5%
24 Dec 2021−6.5%
31 Dec 2021−5.8%
7 Jan 2022−5.3%
14 Jan 2022−2.8%
21 Jan 2022+2.9%
28 Jan 2022+5.1%
4 Feb 2022+3.6%
11 Feb 2022+1.5%
18 Feb 2022−2.0%
25 Feb 2022−1.0%
4 Mar 2022+0.3%
11 Mar 2022+0.2%
17 Mar 2022−7.8%
25 Mar 2022−3.7%
1 Apr 2022−1.9%
8 Apr 2022−1.9%
13 Apr 2022+0.0%
22 Apr 2022−3.2%
29 Apr 2022−9.7%
6 May 2022−0.6%
13 May 2022+8.6%
20 May 2022+10.8%
27 May 2022+16.7%
3 Jun 2022+20.8%
10 Jun 2022+19.6%
17 Jun 2022+22.1%
24 Jun 2022+11.7%
1 Jul 2022+14.8%
8 Jul 2022+17.5%
15 Jul 2022+17.0%
22 Jul 2022+13.4%
29 Jul 2022+14.4%
5 Aug 2022+16.0%
12 Aug 2022+7.3%
19 Aug 2022+2.0%
26 Aug 2022−4.2%
2 Sep 2022−8.1%
9 Sep 2022−11.9%
16 Sep 2022−19.5%
23 Sep 2022−11.4%
30 Sep 2022−14.5%
7 Oct 2022−17.5%
14 Oct 2022−19.5%
21 Oct 2022−17.2%
28 Oct 2022−15.8%
4 Nov 2022−19.5%
11 Nov 2022−17.1%
18 Nov 2022−15.6%
25 Nov 2022−18.7%
2 Dec 2022−18.4%
9 Dec 2022−11.0%
16 Dec 2022−2.4%
23 Dec 2022−1.9%
30 Dec 2022−3.1%
6 Jan 2023−1.9%
13 Jan 2023−3.0%
20 Jan 2023−2.7%
27 Jan 2023−1.0%
3 Feb 2023−1.9%
10 Feb 2023−0.1%
17 Feb 2023+2.8%
24 Feb 2023+4.7%
3 Mar 2023−1.6%
10 Mar 2023−5.9%
17 Mar 2023−9.7%
24 Mar 2023−10.6%
31 Mar 2023−11.6%
6 Apr 2023−10.4%
13 Apr 2023−9.5%
21 Apr 2023−8.2%
28 Apr 2023−10.2%
5 May 2023−7.6%
12 May 2023−10.5%
19 May 2023−10.9%
26 May 2023−14.3%
2 Jun 2023−5.2%
9 Jun 2023−5.1%
16 Jun 2023−5.6%
23 Jun 2023−4.9%
30 Jun 2023−5.4%
7 Jul 2023+1.5%
14 Jul 2023−0.5%
21 Jul 2023−1.3%
28 Jul 2023−5.3%
4 Aug 2023−0.4%
11 Aug 2023+5.8%
18 Aug 2023+5.7%
25 Aug 2023+7.2%
1 Sep 2023+3.5%
8 Sep 2023+14.5%
15 Sep 2023+12.3%
22 Sep 2023+17.9%
29 Sep 2023+16.6%
6 Oct 2023+9.5%
13 Oct 2023+10.8%
20 Oct 2023+8.5%
27 Oct 2023+11.6%
3 Nov 2023+13.0%
12 Nov 2023+12.6%
17 Nov 2023+8.4%
24 Nov 2023+6.7%
1 Dec 2023+6.1%
8 Dec 2023−4.7%
15 Dec 2023−3.8%
22 Dec 2023−6.6%
29 Dec 2023−8.4%
5 Jan 2024−7.5%
12 Jan 2024−3.3%
20 Jan 2024−0.4%
25 Jan 2024+4.9%
2 Feb 2024−5.6%
9 Feb 2024−9.0%
16 Feb 2024−5.6%
23 Feb 2024−2.5%
2 Mar 2024−6.5%
7 Mar 2024−8.3%
15 Mar 2024−11.3%
22 Mar 2024−14.2%
28 Mar 2024−9.6%
5 Apr 2024−8.8%
12 Apr 2024−10.6%
19 Apr 2024−5.0%
26 Apr 2024−13.1%
3 May 2024−10.9%
10 May 2024−12.7%
18 May 2024−9.0%
24 May 2024−16.7%
31 May 2024−15.2%
7 Jun 2024−2.4%
14 Jun 2024+10.5%
21 Jun 2024+17.0%
28 Jun 2024+16.4%
5 Jul 2024+10.1%
12 Jul 2024+8.5%
19 Jul 2024+2.1%
26 Jul 2024+8.1%
2 Aug 2024+14.9%
9 Aug 2024+13.9%
16 Aug 2024+0.8%
23 Aug 2024+9.7%
30 Aug 2024+12.6%
6 Sep 2024+3.3%
13 Sep 2024−1.4%
20 Sep 2024−12.9%
27 Sep 2024−14.7%
4 Oct 2024−1.3%
11 Oct 2024+0.1%
18 Oct 2024−1.9%
25 Oct 2024−1.1%
1 Nov 2024−1.3%
8 Nov 2024+1.2%
14 Nov 2024+0.4%
22 Nov 2024−3.4%
29 Nov 2024−5.1%
6 Dec 2024−4.0%
13 Dec 2024−1.5%
20 Dec 2024+1.6%
27 Dec 2024+0.4%
3 Jan 2025−11.8%
10 Jan 2025−13.1%
17 Jan 2025−14.8%
24 Jan 2025−16.3%
1 Feb 2025−17.3%
7 Feb 2025−20.5%
14 Feb 2025−17.7%
21 Feb 2025−9.0%
28 Feb 2025−4.6%
7 Mar 2025−6.9%
13 Mar 2025−10.5%
21 Mar 2025−12.2%
28 Mar 2025−10.4%
4 Apr 2025−6.0%
11 Apr 2025−4.5%
17 Apr 2025−2.1%
25 Apr 2025−3.7%
2 May 2025−11.0%
9 May 2025−6.9%
16 May 2025+1.4%
23 May 2025−6.7%
30 May 2025+5.4%
6 Jun 2025−0.6%
13 Jun 2025+1.5%
20 Jun 2025+5.6%
27 Jun 2025+13.8%
4 Jul 2025+20.4%
11 Jul 2025+16.2%
18 Jul 2025+19.7%
25 Jul 2025+24.0%
1 Aug 2025+30.7%
8 Aug 2025+17.1%
14 Aug 2025+12.9%
22 Aug 2025+9.7%
29 Aug 2025−6.4%
5 Sep 2025−6.1%
12 Sep 2025−7.6%
19 Sep 2025−5.6%
26 Sep 2025−13.6%
3 Oct 2025−19.2%
10 Oct 2025−19.4%
17 Oct 2025−22.2%
24 Oct 2025−23.7%
31 Oct 2025−26.5%
7 Nov 2025−22.4%
14 Nov 2025−25.9%
21 Nov 2025−21.1%
28 Nov 2025−17.5%
5 Dec 2025−16.0%
12 Dec 2025−15.9%
19 Dec 2025−20.4%
26 Dec 2025−14.6%
2 Jan 2026−14.7%
9 Jan 2026−11.3%
16 Jan 2026−12.0%
23 Jan 2026−8.5%
1 Feb 2026−7.3%
6 Feb 2026−1.8%
13 Feb 2026+9.2%
20 Feb 2026+7.3%
27 Feb 2026+3.5%
6 Mar 2026+8.0%
13 Mar 2026+12.0%
20 Mar 2026+19.6%
27 Mar 2026+10.6%
17 Apr 2026+12.8%
24 Apr 2026+8.3%
30 Apr 2026+11.7%
8 May 2026+3.3%
15 May 2026+1.3%
22 May 2026+0.9%
29 May 2026−3.1%
4 Jun 2026−4.2%
5 Jun 2026−3.9%
10 Jun 2026−7.1%
12 Jun 2026−11.4%
17 Jun 2026−19.3%
19 Jun 2026−15.4%
24 Jun 2026−15.3%
25 Jun 2026−12.8%
1 Jul 2026−16.1%
3 Jul 2026−11.1%
10 Jul 2026−8.7%
17 Jul 2026−6.4%
24 Jul 2026−7.6%
31 Jul 2026−8.3%
7 Aug 2026−9.5%
14 Aug 2026−10.3%
21 Aug 2026−8.3%
28 Aug 2026−5.5%
4 Sep 2026−7.0%
11 Sep 2026−4.3%
18 Sep 2026−8.5%
25 Sep 2026−7.0%
1 Oct 2026−7.9%
9 Oct 2026−9.1%
16 Oct 2026−9.5%
23 Oct 2026−13.3%
30 Oct 2026−16.4%
6 Nov 2026−19.5%
8 Nov 2026−15.5%
13 Nov 2026−16.2%
18 Nov 2026−18.1%
Each bar is one week, from 2016 to now (550 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the NIFTY 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 11 years the share price moved −5% while the NIFTY 500 moved +279%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 22 May 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What changed at Bayer CropScience this quarter?

Two changes stood out: profit up on a year earlier for 7 quarters in a row and operating margin up 4 points on a year earlier.

  1. Profit up on a year earlier for 7 quarters in a row

    In the September 2026 quarter profit was ₹166 crore, +8.5% on a year earlier.

  2. Operating margin up 4 points on a year earlier

    17% in the September 2026 quarter, from 13%.

What dividend does Bayer CropScience pay?

Bayer CropScience paid ₹150 a share in regular dividends in the 12 months to 18 November 2026 (2 payments), a yield of 4.48% at the ₹3,351.80 close on 18 November 2026. The last was an interim dividend of ₹90 a share, ex-date 12 November 2026.

Bayer CropScience dividends since 1 April 2021

Bayer CropScience dividends since 1 April 2021
Ex-dateDividend per shareTypeRecord date
12 Nov 2026Interim₹90Interimsame day
5 Aug 2026Dividend₹60Dividendsame day
14 Nov 2025Interim₹90Interimsame day
7 Aug 2025Dividend₹35Dividendsame day
28 Nov 2024Interim₹90Interimsame day
1 Aug 2024Dividend₹35Dividend—
16 Nov 2023Interim₹105Interimsame day
4 Aug 2023Dividend₹30Dividend—
17 Nov 2022Interim₹100Interim19 Nov 2022
4 Aug 2022Dividend₹25Dividend—
11 Nov 2021Special₹125Special13 Nov 2021
27 Jul 2021Dividend₹25Dividend—

Amounts as the company declared them on the exchange. A dividend goes to whoever owns the shares before the ex-date.

5 of 5Of the last 5 financial years, years with an exchange dividend record

Yes. Bayer CropScience Ltd paid out 98% of its profit as dividends in FY26, and it paid a dividend in each of its last 14 reported years.

From the exchange corporate-actions record, read 18 November 2026.

What are Bayer CropScience's latest quarterly results?

For July to September 2026 (the quarter ended 30 September 2026), Bayer CropScience reported revenue of ₹1,251 crore, down 19.4% from ₹1,553 crore a year earlier, and a profit of ₹166 crore, up 8.5% from ₹153 crore.

Bayer CropScience results: July to September 2026 against a year earlier

Bayer CropScience results: July to September 2026 against a year earlier
MeasureJuly to September 2026July to September 2025Change
Revenue₹1,251 crore₹1,553 crore−19.4%
Profit₹166 crore₹153 crore+8.5%
Earnings per share₹36.98₹33.98+8.8%
Operating margin17.4%13.2%+4.2 points

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

What is the Bayer CropScience share price history?

Bayer CropScience closed at ₹3,351.80 on 18 November 2026, down 26.2% from ₹4,544.60 a year earlier (21 November 2025) and down 29.3% over five years. Its highest weekly close since March 2016 was ₹6,874.55 on 2 August 2024.

Bayer CropScience share price: then and now

Bayer CropScience share price: then and now
WhenCloseChange to 18 Nov 2026
1 week ago · 11 Nov 2026₹3,603.80−7.0%
1 month ago · 19 Oct 2026₹3,548.20−5.5%
6 months ago · 15 May 2026₹4,349.80−22.9%
1 year ago · 21 Nov 2025₹4,544.60−26.2%
3 years ago · 17 Nov 2023₹5,371.00−37.6%
5 years ago · 18 Nov 2021₹4,743.00−29.3%
10 years ago · 18 Nov 2016₹3,916.30−14.4%
Earliest weekly close in our records · 11 Mar 2016₹3,542.70−5.4%
Highest weekly close since March 2016 · 2 Aug 2024₹6,874.55−51.2%
Lowest weekly close since March 2016 · 2 Aug 2019₹2,998.45+11.8%
52-week high (weekly close) · 17 Apr 2026₹4,898.20−31.6%
52-week low (weekly close) · 30 Oct 2026₹3,256.70+2.9%

Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 18 November 2026.

What is the latest news on Bayer CropScience?

18 Nov 2026: Bayer CropScience closed at ₹3,351.80, down 7.0% on the week and down 5.5% on the month. 12 Nov 2026: ex-date for an interim dividend of ₹90 a share.

Earlier

  • Results for July to September 2026: Revenue down 19.4% and profit up 8.5% on a year earlier.
  • 5 Aug 2026: ex-date for a dividend of ₹60 a share.

What to watch in Bayer CropScience's next results?

When Bayer CropScience reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Revenue against the same quarter a year earlier.

  • Revenue against the same quarter a year earlier. In the Sep 2026 quarter, revenue was −19.4% on a year earlier, and the last four quarters averaged −3.4%.
  • Whether the operating margin stays near 17.4%. It is 4.2 percentage points higher than four quarters earlier.
  • Net profit against the same quarter a year earlier. In the Sep 2026 quarter, profit was +8.5% on a year earlier. It has grown on a year earlier for 7 quarters in a row.

Which stock lists is Bayer CropScience on?

Bayer CropScience is on 2 of our India lists: Dividend stocks and Small & mid cap stocks.

Is Bayer CropScience profitable?

Bayer CropScience Ltd earned ₹166 Cr of net profit in the Sep 2026 quarter, +8.5% on the same quarter a year earlier. That is the 7th quarter in a row of profit growth. Full-year FY26 profit was ₹689 Cr. Over 10 years profit has grown 8.1% a year on average. The same quarter a year earlier earned ₹153 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The Sep 2026 quarter's profit is 13.3% of that quarter's revenue.

For the full year, FY26 profit was ₹689 Cr (+21.3% on the year before).

Why profit moved: revenue changed −19.4% on a year earlier and the margin moved +4.2 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +54.9% and revenue −3.4%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

How much revenue does Bayer CropScience make, and is it growing?

Bayer CropScience Ltd reported ₹1,251 Cr of revenue in the Sep 2026 quarter, −19.4% on the same quarter a year earlier. Over 10 years it has grown 7.4% a year on average. The last full year, FY26, came in at ₹5,675 Cr. The last four reported quarters add to ₹5,293 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹5,675 Cr, +3.7% on the year before.

Recent pace: the last four quarters grew −3.4% on average, against 7.4% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −5.0%, against +1.7% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +22.5%, against +13.5% a year (accelerating).

How much of every ₹100 of sales does Bayer CropScience keep?

Bayer CropScience Ltd's operating margin was 17.4% in the Sep 2026 quarter, 4.2 percentage points higher than the same quarter a year ago. Across 14 years it has been between 4.8% and 20.1%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +4.2 percentage points on the year while gross margin changed +8.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Is Bayer CropScience's profit turning into cash?

Over the last 3 years, 115% of Bayer CropScience Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,078 Cr of operating cash against ₹689 Cr of profit. After ₹40.0 Cr of spending on assets, ₹1,039 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 115% of profit came in as cash: the cash cycle got 44 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Where does Bayer CropScience's cash go?

Bayer CropScience Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 193 days in FY26, up from 149 days in FY21. It spent ₹112 Cr on assets over the last 3 years. Customers take 72 days to pay, and stock sits for 289 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹5,675 Cr, each day of that cycle ties up about ₹15.5 Cr, so roughly ₹3,001 Cr is tied up in the business at any time.

FY26: customers took 72 days to pay and stock sat for 289 days, about 9.5 months of sales sitting as stock, for a full cycle of 193 days, longer than FY21's 149.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 289 days. Customers pay about 72 days after that. Suppliers are paid at 167 days. Together that makes the 193-day cycle.

Spending on assets: ₹112 Cr over the last 3 years, against ₹253 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹127 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

What is Bayer CropScience's P/E ratio, and how does it compare with its own history?

Bayer CropScience Ltd's P/E is 20.2×, about the lowest it has ever been. Its usual P/E (the middle reading) is 40.9×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

20.2×P/E · lower than 100% of its last 10 years
2.22PEG · today, derived from 3-year earnings growth

Why the multiple is where it is: over the past year earnings per share moved +22.5% while the price moved −26.2%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 3 years the price moved −14.5% a year; about −4.1% a year came from earnings growth and about −10.4 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Is the Bayer CropScience business getting better or worse?

Bayer CropScience Ltd's business is getting better. Profit growth was −21.3% 6 quarters ago and has recovered to +22.5%, with ROCE rising at 29.1% (year to Mar 2026). This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

FallingRevenue growth · latest (Sep 2026) −5.0%, range −5.0% to +33.9%
FlatProfit growth · latest (Sep 2026) +22.5%, range −23.4% to +29.0%
FlatEPS growth · latest (Sep 2026) +22.4%, range −23.3% to +28.8%
RisingROCE · latest (year to Mar 2026) 29.1%, range 20.4% to 32.0%

Why it matters: a lasting rise from a low is what this page is built to show.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue+3.7%+3.4%+5.9%+7.4%
Profit+21.3%−3.1%+6.9%+8.1%
EPS+21.3%−3.1%+6.9%+5.6%
Share price−26.2%−14.5%−6.7%−1.5%
−19.4%Revenue growth (Sep 2026) · latest quarter against a year ago
+8.5%Profit growth (Sep 2026) · latest quarter against a year ago
7.4%Revenue, 10 years · yearly growth over the long run

How much does Bayer CropScience earn on its capital?

Bayer CropScience Ltd earned a ROCE of 29% in FY26. That is up from a low of 20% in Dec 2006. Its return on capital used (ROIC) is 17.4 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 12.1% net margin and 1.00× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 12.1% net margin × 1.00× asset turnover × 1.92× leverage (assets divided by equity) ≈ 23.2% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 29.4% − 12.0% = +17.4 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.

The 29.4% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 34.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Does Bayer CropScience have too much debt?

Bayer CropScience Ltd has total debt of ₹70.0 Cr against shareholder equity of ₹3,184 Cr as of Sep 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.03 in FY22 to 0.03 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

What is the Bayer CropScience shareholding pattern?

No group of Bayer CropScience Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved −0.6 points over the same period, to 11.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Foreign institutions: +0.7 points over 8 quarters, to 4.0%; Domestic institutions: −0.6 points over 8 quarters, to 11.5%; Promoters: +0.0 points over 8 quarters, to 71.4%.

How far is Bayer CropScience from balance-sheet trouble?

For Bayer CropScience Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

How does Bayer CropScience rank in its industry?

63.0 out of 100, rank 4 of 25 in Pesticides/Agrochemicals, with 85% of the evidence available.

Bayer CropScience Ltd scores 63.0 out of 100 against the 25 companies it is compared with in Pesticides/Agrochemicals, ranking 4. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 24.5 + 19.3 + 10.6 + 8.6 = 63. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is Bayer CropScience compared with?

Bayer CropScience ranks 4 of 25 Pesticides/Agrochemicals companies on the 4-Factor Sector Score, with 63.0 out of 100.

  1. 1Titan Biotech Ltdbreaking out · Most evidence points up · 87% evidence76.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 31.3/35 · Revenue 31.8% · Profit 38.7% · Operating margin change 3 points · 95% evidenceCapital efficiency 21.3/25 · ROCE 22.8% (year to Mar 2026) · Operating margin 19.7% · 95% evidenceValuation 5.4/20 · P/E 55.2× · PEG — · 50% evidenceRelative strength 18.6/20 · Strength vs its industry (price vs its 52-week average, weekly) 44.3% · Strength vs NIFTY 500 (same reading) 21.3% · 1 year 177.2% · 100% evidence · 4 of 12 weeks aheadExact sum: 31.3 + 21.3 + 5.4 + 18.6 = 76.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  2. 2Sharda Cropchem LtdSHARDACROP · basing · Most evidence points up · 100% evidence66.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 28.2/35 · Revenue 17.3% · Profit 42.5% · Operating margin change 2 points · 100% evidenceCapital efficiency 19.6/25 · ROCE 30.2% (year to Mar 2026) · Operating margin 15.6% · 100% evidenceValuation 11.5/20 · P/E 9.8× · PEG 2.26 · 100% evidenceRelative strength 7.6/20 · Strength vs its industry (price vs its 52-week average, weekly) -5.2% · Strength vs NIFTY 500 (same reading) -21.1% · 1 year -12.6% · 100% evidence · 0 of 12 weeks aheadExact sum: 28.2 + 19.6 + 11.5 + 7.6 = 66.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  3. 3Jubilant Ingrevia LtdJUBLINGREA · quiet · Most evidence points up · 93% evidence65.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 27.4/35 · Revenue 15.4% · Profit 21.9% · Operating margin change 3 points · 100% evidenceCapital efficiency 13.8/25 · ROCE 11.4% (year to Mar 2026) · Operating margin 15.2% · 100% evidenceValuation 12.9/20 · P/E 26.7× · PEG 1.16 · 65% evidenceRelative strength 11.2/20 · Strength vs its industry (price vs its 52-week average, weekly) 3.8% · Strength vs NIFTY 500 (same reading) -13.5% · 1 year -18.5% · 100% evidence · 2 of 12 weeks aheadExact sum: 27.4 + 13.8 + 12.9 + 11.2 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  4. 4Bayer CropScience Ltd this pageBAYERCROP · quiet · Evidence leans up · 85% evidence63.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.5/35 · Revenue -5% · Profit 22.5% · Operating margin change 4 points · 100% evidenceCapital efficiency 19.3/25 · ROCE 29.1% (year to Mar 2026) · Operating margin 17.4% · 100% evidenceValuation 10.6/20 · P/E 20.2× · PEG 2.22 · 100% evidenceRelative strength 8.6/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -22.1% · 1 year -26.2% · 25% evidence · 0 of 12 weeks aheadExact sum: 24.5 + 19.3 + 10.6 + 8.6 = 63 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  5. 5Dhanuka Agritech LtdDHANUKA · quiet · Evidence leans up · 100% evidence54.7out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 10.0/35 · Revenue 0% · Profit 0.7% · Operating margin change 0 points · 100% evidenceCapital efficiency 19.8/25 · ROCE 25.9% (year to Mar 2026) · Operating margin 23.3% · 100% evidenceValuation 11.4/20 · P/E 14.8× · PEG 2.07 · 100% evidenceRelative strength 13.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 0.8% · Strength vs NIFTY 500 (same reading) -16.1% · 1 year -23.7% · 100% evidence · 0 of 12 weeks aheadExact sum: 10 + 19.8 + 11.4 + 13.5 = 54.7 · What this means: Relative strength against the index is -16.1%, and revenue and profit growth are weak.
  6. 6Advance Agrolife LtdADVANCE · losing its lead · Evidence leans up · 68% evidence54.7out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 19.0/35 · Revenue 49.4% · Profit 55.2% · Operating margin change -4 points · 100% evidenceCapital efficiency 13.7/25 · ROCE 19.6% (year to Mar 2026) · Operating margin 7.7% · 100% evidenceValuation 10.1/20 · P/E 17.4× · PEG — · 15% evidenceRelative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 2.3% · 1 year -8.5% · 25% evidence · 10 of 12 weeks aheadExact sum: 19 + 13.7 + 10.1 + 11.9 = 54.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  7. 7Punjab Chemicals & Crop Protection LtdPUNJABCHEM · quiet · Evidence leans up · 75% evidence53.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 19.6/35 · Revenue 14% · Profit 13.2% · Operating margin change -1 points · 100% evidenceCapital efficiency 13.2/25 · ROCE 18.6% (year to Mar 2026) · Operating margin 9.2% · 100% evidenceValuation 11.0/20 · P/E 17.9× · PEG — · 50% evidenceRelative strength 9.2/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -19% · 1 year -34.1% · 25% evidence · 3 of 12 weeks aheadExact sum: 19.6 + 13.2 + 11 + 9.2 = 53 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  8. 8Dharmaj Crop Guard LtdDHARMAJ · quiet · Evidence leans up · 75% evidence52.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 14.5/35 · Revenue 3.8% · Profit 14.3% · Operating margin change -2 points · 100% evidenceCapital efficiency 14.7/25 · ROCE 16.8% (year to Mar 2026) · Operating margin 7.2% · 100% evidenceValuation 13.2/20 · P/E 15.1× · PEG — · 50% evidenceRelative strength 10.0/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -9.7% · 1 year -0.9% · 25% evidence · 5 of 12 weeks aheadExact sum: 14.5 + 14.7 + 13.2 + 10 = 52.4 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far.
  9. 9Best Agrolife LtdBESTAGRO · quiet · Evidence leans up · 90% evidence52.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.7/35 · Revenue -19.6% · Profit 100% · Operating margin change 10 points · 100% evidenceCapital efficiency 10.0/25 · ROCE 5.2% (year to Mar 2026) · Operating margin 24.8% · 100% evidenceValuation 11.3/20 · P/E 10.8× · PEG — · 50% evidenceRelative strength 6.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -4.7% · Strength vs NIFTY 500 (same reading) -20.8% · 1 year -26.5% · 100% evidence · 7 of 12 weeks aheadExact sum: 24.7 + 10 + 11.3 + 6 = 52 · What this means: Earnings are strong; relative strength in its sector is -4.7% and the one-year return is -26.5%.
  10. 10Meghmani Organics LtdMOL · quiet · Evidence leans down · 68% evidence49.7out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 20.9/35 · Revenue -5.2% · Profit 100% · Operating margin change 2 points · 100% evidenceCapital efficiency 7.7/25 · ROCE 6.7% (year to Mar 2026) · Operating margin 10.9% · 100% evidenceValuation 10.4/20 · P/E 15.6× · PEG — · 15% evidenceRelative strength 10.7/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) -2.3% · 1 year -23.9% · 25% evidence · 8 of 12 weeks aheadExact sum: 20.9 + 7.7 + 10.4 + 10.7 = 49.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  11. 11Excel Industries LtdEXCELINDUS · losing its lead · Evidence leans down · 68% evidence49.0out of 100GrowthCapitalValuationRelative
  12. 12UPL LtdUPL · basing · Evidence leans down · 82% evidence48.9out of 100GrowthCapitalValuationRelative
  13. 13Rallis India LtdRALLIS · quiet · Evidence leans down · 85% evidence47.9out of 100GrowthCapitalValuationRelative
  14. 14Shivalik Rasayan LtdSHIVALIK · turning · Evidence leans down · 67% evidence47.9out of 100GrowthCapitalValuationRelative
  15. 15Bhagiradha Chemicals & Industries LtdBHAGCHEM · quiet · Evidence leans down · 83% evidence47.7out of 100GrowthCapitalValuationRelative
  16. 16Epigral LtdEPIGRAL · quiet · Evidence leans down · 75% evidence46.8out of 100GrowthCapitalValuationRelative
  17. 17India Pesticides LtdIPL · quiet · Evidence leans down · 75% evidence46.0out of 100GrowthCapitalValuationRelative
  18. 18Sumitomo Chemical India LtdSUMICHEM · quiet · Evidence leans down · 85% evidence43.7out of 100GrowthCapitalValuationRelative
  19. 19Insecticides India LtdINSECTICID · quiet · Evidence leans down · 90% evidence42.8out of 100GrowthCapitalValuationRelative
  20. 20Bharat Rasayan LtdBHARATRAS · basing · Evidence leans down · 90% evidence42.4out of 100GrowthCapitalValuationRelative
  21. 21GSP Crop Science LtdGSPCROP · quiet · Evidence leans down · 63% evidence39.8out of 100GrowthCapitalValuationRelative
  22. 22P I Industries LtdPIIND · quiet · Most evidence points down · 75% evidence34.5out of 100GrowthCapitalValuationRelative
  23. 23NACL Industries LtdNACLIND · basing · Most evidence points down · 90% evidence32.9out of 100GrowthCapitalValuationRelative
  24. 24Heranba Industries LtdHERANBA · quiet · Most evidence points down · 71% evidence31.9out of 100GrowthCapitalValuationRelative
  25. 25Astec Lifesciences LtdASTEC · quiet · Most evidence points down · 71% evidence31.3out of 100GrowthCapitalValuationRelative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pesticides/Agrochemicals, all 25 compared on one page.

Which companies are close to Bayer CropScience in size?

Bayer CropScience is the 4th largest of 25 Pesticides/Agrochemicals companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: UPL, P I Industries and Sumitomo Chemical India. Just below it: Jubilant Ingrevia, Sharda Cropchem and Dhanuka Agritech.

Pesticides/Agrochemicals companies close in size

  1. UPL Ltd ₹46,584 crore
  2. P I Industries Ltd ₹24,639 crore
  3. Sumitomo Chemical India Ltd ₹16,684 crore
  4. Bayer CropScience Ltd ₹15,064 crore
  5. Jubilant Ingrevia Ltd ₹9,348 crore
  6. Sharda Cropchem Ltd ₹6,305 crore
  7. Dhanuka Agritech Ltd ₹4,173 crore

All 25 Pesticides/Agrochemicals companies, largest first

Companies close in size in other industries

  1. Astrazeneca Pharma India Ltd ₹15,109 crore · Pharma - MNC bulk Drugs
  2. Devyani International Ltd ₹15,107 crore · Quick Service Restaurant - QSR
  3. Bayer CropScience Ltd ₹15,064 crore
  4. Swan Defence and Heavy Industries Ltd ₹15,047 crore · Ship - Docks/Breaking/Repairs
  5. Anupam Rasayan India Ltd ₹15,040 crore · Speciality Chemicals

What else do people ask about Bayer CropScience?

What were Bayer CropScience's latest quarterly results?

Bayer CropScience Ltd reported revenue of ₹1,251 Cr and net profit of ₹166 Cr for the Sep 2026 quarter. Revenue fell 19.4% and profit rose 8.5% compared with a year earlier. Earnings per share were ₹36.98.

The operating margin was 17.4%, 4.2 percentage points higher than a year earlier (as of 18 November 2026).

What is Bayer CropScience's market cap?

Bayer CropScience Ltd's market capitalisation is ₹15,064 Cr at a share price of ₹3,351.80. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026).

How is Bayer CropScience performing?

Bayer CropScience Ltd's share price has been falling for 59 weeks. In its latest quarter, revenue fell 19.4% and profit rose 8.5% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 32 weeks running (as of 18 November 2026).

Will Bayer CropScience's share price go up?

This page does not forecast Bayer CropScience Ltd's share price. What it shows instead: the share price is ₹3,351.80, and it has been falling for 59 weeks. Its P/E of 20.2× is higher than 0% of its own last 10 years (as of 18 November 2026).

Who owns Bayer CropScience?

Promoters own 71.4% of Bayer CropScience Ltd, foreign institutions 4.0%, domestic institutions 11.5% and the public 13.1% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 18 November 2026).

Does Bayer CropScience have too much debt?

No, Bayer CropScience Ltd has little debt: its debt is 0.02× its equity, and its operating profit is 48 times its interest bill. At Sep 2026 borrowings were ₹70.0 Cr against equity of ₹3,184 Cr.

So the returns on this page come from the business, not borrowed money (as of 18 November 2026).

Where is Bayer CropScience in its business cycle?

Bayer CropScience Ltd's FY26 operating margin was 15.4%, against a 14-year range of 4.8% to 20.1%. The latest quarter was 17.4%, near the top of its own range.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026).

What could break the Bayer CropScience story?

The main question: earnings per share (last four quarters) moved +22.5% while the share price moved −26.2%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026).

Is Bayer CropScience a stock worth studying right now?

What the numbers show: Bayer CropScience Ltd's earnings have grown faster than its share price. Earnings per share grew +22.5% in a year while the price moved −26.2%. The main open question: whether the price catches up with earnings that have already grown.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026).

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 18 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.